Oppenheimer Maintains Outperform on Chemed, Raises Price Target to $625
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Michael Wiederhorn has maintained an Outperform rating on Chemed (NYSE:CHE) and increased the price target from $590 to $625.
January 17, 2024 | 3:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer has reaffirmed Chemed's Outperform rating and raised the price target from $590 to $625, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst like Michael Wiederhorn suggests a strong conviction in Chemed's future performance. This typically instills confidence in current and potential investors, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100